Enterprise record
Alpha ID: alpha:company:2eb0d5fc-bfaf-41de-8ee0-6168096e09e6Version: public-1:d751713988987e9331980363e24189ceAs of: 2026-10-05T20:25:47.48638+00:00
20 published Claims6 sources
Governance record
Record overview
Explore SUPERNUS PHARMACEUTICALS, INC.'s published governance Claims, committee structure, and linked sources. Each item reflects the scope and dates of its source.
About this record →- Company
- SUPERNUS PHARMACEUTICALS, INC.
- Published Claims
- 20
- Evidence records
- 6
- Record version
- public-1:d751713988987e9331980363e24189ce
Record highlights
Only published Claims appear in these highlights.
Financials →
No source-linked Claim published yet.
Shareholders →
No source-linked Claim published yet.
Compensation →
No source-linked Claim published yet.
Legal →
No source-linked Claim published yet.
Committee overview
Committee summaries link to the published Claim and its source evidence.
A committee summary is not published in this record. Review the Board section for available leadership and appointment Claims.
Key governance topics
Counts describe published Claims in this record.
Key Claims
- Leadership RoleCharles W. Newhall, III: Chairman of the BoardSEC DEF 14A 0001104659-26-053111
- Leadership RoleBethany L. Sensenig: DirectorDEF 14A tm261453-1_def14a.htm
- Leadership RoleCarrolee Barlow: DirectorDEF 14A tm261453-1_def14a.htm
- Leadership RoleCarrolee Barlow, M.D., Ph.D.: DirectorSEC DEF 14A 0001104659-26-053111
Board and committees
Critical-risk oversight
Critical-risk oversight coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageFinancial statements
Published financial observations retain their reported values, periods, and sources. Coverage may be partial; this is not a reconstructed complete financial statement.
All financials coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageControl and shareholders
Control and shareholders coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageCompensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAuditors, advisors and reporting
Auditors, advisors and reporting coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageLegal
Legal coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAI governance
AI governance coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageEvidence, history and coverage
Additional published Claims
Published evidence records
6 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Alpha canonical company public projection
canonical identity · Source published: Date unavailable · Retrieved: Oct 5, 2026
Supports 3 claims
- Legal Name: SUPERNUS PHARMACEUTICALS, INC. · Claim reviewed: Oct 5, 2026
- Entity Status: Public listing published · Claim reviewed: Oct 5, 2026
- Published Fact: US · Claim reviewed: Oct 5, 2026
SEC DEF 14A 0001104659-26-053111
sec def 14a · Source published: Apr 30, 2026 · Retrieved: Sep 13, 2026
Supports 9 claims
- Leadership Role: Charles W. Newhall, III: Chairman of the Board · Claim reviewed: Oct 5, 2026
- Leadership Role: Carrolee Barlow, M.D., Ph.D.: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Georges Gemayel, Ph.D.: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Frank Mottola: Senior Vice President, Chief Technical Operations Officer · Claim reviewed: Oct 5, 2026
- Leadership Role: Jack A. Khattar: President, Chief Executive Officer and Secretary · Claim reviewed: Oct 5, 2026
- Leadership Role: Jonathan Rubin, M.D.: Senior Vice President, Chief Medical Officer, Research and Development · Claim reviewed: Oct 5, 2026
- Leadership Role: Padmanabh P. Bhatt, Ph.D.: Senior Vice President of Intellectual Property, Chief Scientific Officer · Claim reviewed: Oct 5, 2026
- Leadership Role: Timothy C. Dec: Senior Vice President, Chief Financial Officer · Claim reviewed: Oct 5, 2026
- Leadership Role: William Todd Horich, Ph.D., MBA: Senior Vice President, Commercial Operations, Marketing, and Market Access · Claim reviewed: Oct 5, 2026
DEF 14A tm261453-1_def14a.htm
sec proxy · Source published: Apr 30, 2026 · Retrieved: Sep 2, 2026
Supports 5 claims
- Leadership Role: Bethany L. Sensenig: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Carrolee Barlow: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Frederick M. Hudson: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Georges Gemayel: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Jack A. Khattar: Director · Claim reviewed: Oct 5, 2026
SUPN DEF 14A executive officers
sec filing · Source published: Apr 30, 2026 · Retrieved: May 5, 2026
Supports 1 claim
- Leadership Role: Jonathan Rubin: Senior Vice President, Chief Medical Officer, Research and Development · Claim reviewed: Oct 5, 2026
SUPN DEF 14A executive officers
sec filing · Source published: Apr 30, 2026 · Retrieved: May 5, 2026
Supports 1 claim
- Leadership Role: Prat S. Bhatt: Senior Vice President of Intellectual Property, Chief Scientific Officer · Claim reviewed: Oct 5, 2026
SUPN DEF 14A executive officers
sec filing · Source published: Apr 30, 2026 · Retrieved: May 5, 2026
Supports 1 claim
- Leadership Role: William Todd Horich: Senior Vice President, Commercial Operations, Marketing, and Market Access · Claim reviewed: Oct 5, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-05
- Board and committees
- published
- Critical-risk oversight
- not observed
- Financial statements
- not observed
- Control and shareholders
- not observed
- Compensation
- not observed
- Auditors, advisors and reporting
- not observed
- Legal
- not observed
- AI governance
- not observed